| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $38,381,707 ) (Continued on the next page) |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL166606 | Targeting Energetics to Improve Outcomes in Hypertrophic Cardiomyopathy | 001 | 3 | NIH | 3/13/2026 | $23,581 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL166608 | Disease-specific risk factors for thrombosis following vascular interventions | 000 | 4 | NIH | 7/30/2026 | $660,794 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K08DA058052 | Impact of initial buprenorphine prescribing strategies on retention in care for patients with opioid use disorder | 001 | 4 | NIH | 7/31/2026 | $0 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K08DA058052 | Impact of initial buprenorphine prescribing strategies on retention in care for patients with opioid use disorder | 000 | 4 | NIH | 4/27/2026 | $185,085 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | D4054828 | Graduate Psychology Education Programs | 01 | 2 | HRSA | 6/23/2026 | $0 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | D4054828 | Graduate Psychology Education Programs | 00 | 2 | HRSA | 5/28/2026 | $449,972 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DA058367 | PrEP and MOUD Rapid Access for Persons who Inject Drugs: the CHORUS+ Study | 000 | 4 | NIH | 7/6/2026 | $1,068,172 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HD113143 | Association of maternal, fetal and placental biomarkers with neonatal neuroimaging and development following in-utero opioid exposure | 000 | 2 | NIH | 8/6/2026 | $834,420 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK140570 | THRIVE-DM: Improving Diabetes Care with Strategies for Addressing Health-Related Social Needs and Community Partnerships | 000 | 3 | NIH | 8/11/2026 | $165,349 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK140570 | THRIVE-DM: Improving Diabetes Care with Strategies for Addressing Health-Related Social Needs and Community Partnerships | 000 | 3 | NIH | 8/11/2026 | $344,666 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK134616 | Significance of Tubuloglomerular Feedback in SGLT1 and SGLT2 Inhibition in Diabetic Kidney Disease | 000 | 5 | NIH | 1/22/2026 | $414,060 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | 90ZT0224 | The Moving Forward Initiative for Survivors of Torture and Their Families | 00 | 5 | ACF | 8/12/2026 | $487,341 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AA030460 | Gabapentin to Reduce Alcohol and Improve Viral Load Suppression - Promoting "Treatment as Prevention" | 001 | 5 | NIH | 7/14/2026 | $172,325 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AA030460 | Gabapentin to Reduce Alcohol and Improve Viral Load Suppression - Promoting "Treatment as Prevention" | 000 | 5 | NIH | 7/1/2026 | $520,034 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL178832 | Niche-specific endothelial mechanisms regulating the extravasation of hematopoietic stem cells | 001 | 2 | NIH | 3/24/2026 | $21,594 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL178832 | Niche-specific endothelial mechanisms regulating the extravasation of hematopoietic stem cells | 000 | 2 | NIH | 2/24/2026 | $683,816 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK118267 | Nucleophosmin Centered Diagnostics and Treatment of Ischemic Acute Kidney Injury | 000 | 7 | NIH | 3/24/2026 | $555,038 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK133404 | Investigation of the role of VEGFA in harnessing cholangiocyte-driven liver regeneration | 000 | 5 | NIH | 4/3/2026 | $577,631 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23DA061933 | Promoting positive parenting for mothers with OUD: Implementation of a video-coaching intervention in pediatrics | 001 | 2 | NIH | 4/6/2026 | $193,523 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23MD020103 | Designing and piloting clinic-based health information technology to improve WIC retention | 000 | 2 | NIH | 5/26/2026 | $166,738 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01CA299475 | Development of Systems and Education for Cervical Cancer prevention (DOSE-CC) | 000 | 2 | NIH | 4/27/2026 | $694,181 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23HL165097 | From Hypertensive Pregnancy to Heart Health: Understanding and Addressing Multi-Level Barriers to Cardiovascular Health after Hypertensive Disorders of Pregnancy | 000 | 3 | NIH | 7/22/2026 | $98,571 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23HL165097 | From Hypertensive Pregnancy to Heart Health: Understanding and Addressing Multi-Level Barriers to Cardiovascular Health after Hypertensive Disorders of Pregnancy | 000 | 3 | NIH | 7/22/2026 | $94,477 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DA046527 | Researching Effective Strategies to Prevent Opioid Death (RESPOND) | 001 | 9 | NIH | 7/27/2026 | $797,674 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K01HL151902 | Building methods to assess and address cardiovascular health in transgender adults | 003 | 5 | NIH | 2/11/2026 | $166,277 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K01DK146245 | Uremic Toxins, a consequence of CKD, as key mediators of CKM-associated PAD | 000 | 1 | NIH | 8/13/2026 | $152,777 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK142896 | The Impact of Allostatic Load on Kidney Disease | 000 | 1 | NIH | 7/7/2026 | $918,576 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R03CA308637 | Personalized Spatial Regulatory Networks to Decode Breast Cancer Microenvironments | 000 | 1 | NIH | 6/12/2026 | $178,000 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R56AI203669 | The impact of HIV LTR intra- and inter-individual sequence variability on HIV latency and reactivation dynamics | 000 | 1 | NIH | 8/20/2026 | $765,050 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23DK146149 | First person storytelling: Improving kidney education for Spanish speakers with advanced kidney disease | 000 | 1 | NIH | 1/26/2026 | $194,147 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R13DA064395 | Academic Consortium of Criminal Justice Health | 000 | 2 | NIH | 5/25/2026 | $77,200 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23DK146149 | First person storytelling: Improving kidney education for Spanish speakers with advanced kidney disease | 001 | 1 | NIH | 7/15/2026 | $0 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K08HL177161 | Developing models of placenta-driven developmental lung injury in human preeclampsia | 000 | 2 | NIH | 8/19/2026 | $166,752 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R33DA060588 | Massachusetts HIV and Justice-Involved Populations Research Network | 000 | 4 | NIH | 8/5/2026 | $1,532,176 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | DP2DA066177 | The LINK Intervention: Using informatics and implementation science to reduce missed opportunities to prevent opioid overdose and HIV infection | 000 | 1 | NIH | 5/5/2026 | $2,670,000 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R33DA059856 | Substance Use Prevention for Recently displaced Adults (SUPRA) | 001 | 3 | NIH | 3/3/2026 | $118,239 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R33DA059856 | Substance Use Prevention for Recently displaced Adults (SUPRA) | 000 | 3 | NIH | 2/26/2026 | $556,407 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AI191221 | TACTIC: Tuberculosis Active Case Tracking via Interpersonal Connections | 001 | 1 | NIH | 7/3/2026 | $296,010 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AI191221 | TACTIC: Tuberculosis Active Case Tracking via Interpersonal Connections | 000 | 1 | NIH | 6/19/2026 | $487,764 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | RM1DA066198 | PREP-TALK: Transforming Hospitalization into a PrEP Engagement Opportunity for People Who Use Drugs | 000 | 1 | NIH | 7/20/2026 | $2,066,706 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AG093132 | Mosaic loss of the Y chromosome in transthyretin (ATTR) cardiac amyloidosis | 000 | 1 | NIH | 3/5/2026 | $763,561 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AI197970 | HIV-1 antibodies in the presence of tuberculosis and other coinfections | 000 | 1 | NIH | 3/27/2026 | $872,596 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AI198006 | Mycobacterium Tuberculosis impact on HIV reservoir Clearance (MyTHIC) | 000 | 1 | NIH | 5/4/2026 | $795,622 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R33DA062217 | A Universal Primary Care Based Intervention to Reduce Youth Overdose Risk | 000 | 2 | NIH | 7/30/2026 | $1,106,433 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R25DA033211 | Advancing Clinical Research Training within Addiction Residency Programs | 000 | 13 | NIH | 2/18/2026 | $363,891 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01MH138549 | Adaptive interventions to improve posttraumatic stress (PTSD) treatment access, engagement, and effectiveness in routine care | 000 | 2 | NIH | 7/15/2026 | $863,400 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R25DA059908 | Clinical Undergraduate Research in Addictions - Training and Experiences (CURATE) Program | 001 | 2 | NIH | 7/6/2026 | $132,507 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23MD019068 | Adapting an Evidence-Based Intervention to Improve the Hospital Discharge Process for Patients with Limited English Proficiency | 002 | 4 | NIH | 7/14/2026 | $0 |
| | 2026 | 2026 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23MD019068 | Adapting an Evidence-Based Intervention to Improve the Hospital Discharge Process for Patients with Limited English Proficiency | 001 | 4 | NIH | 6/19/2026 | $162,202 |
|
